Q2 Earnings Estimate for CVRx Issued By William Blair

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Equities research analysts at William Blair issued their Q2 2025 earnings estimates for shares of CVRx in a report issued on Monday, July 7th. William Blair analyst B. Vazquez anticipates that the company will earn ($0.52) per share for the quarter. William Blair has a "Strong-Buy" rating on the stock. The consensus estimate for CVRx's current full-year earnings is ($1.91) per share. William Blair also issued estimates for CVRx's Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($2.00) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.39) EPS and FY2026 earnings at ($1.96) EPS.

CVRx (NASDAQ:CVRX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.03. CVRx had a negative net margin of 97.49% and a negative return on equity of 79.04%. The business had revenue of $12.35 million during the quarter, compared to the consensus estimate of $14.68 million.

Several other research analysts also recently commented on the stock. Lake Street Capital dropped their price objective on shares of CVRx from $19.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, April 8th. JPMorgan Chase & Co. reaffirmed an "underweight" rating and issued a $7.00 price target (down previously from $15.00) on shares of CVRx in a report on Friday, May 9th. Piper Sandler lowered their price target on shares of CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, Canaccord Genuity Group lowered their price target on shares of CVRx from $23.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $14.50.

CVRx Price Performance

Shares of CVRX traded down $0.13 during midday trading on Thursday, hitting $6.83. 111,973 shares of the company traded hands, compared to its average volume of 305,075. The firm has a 50 day moving average of $6.37 and a 200-day moving average of $10.25. CVRx has a 52 week low of $4.30 and a 52 week high of $18.55. The stock has a market cap of $178.06 million, a price-to-earnings ratio of -3.13 and a beta of 1.23. The company has a debt-to-equity ratio of 0.71, a quick ratio of 13.45 and a current ratio of 14.82.

Insider Activity at CVRx

In other CVRx news, Director Kirk G. Nielsen purchased 61,200 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was purchased at an average price of $5.23 per share, with a total value of $320,076.00. Following the acquisition, the director owned 1,899,168 shares in the company, valued at approximately $9,932,648.64. The trade was a 3.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders have bought 78,666 shares of company stock valued at $411,031. 18.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its stake in shares of CVRx by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company's stock worth $49,000 after acquiring an additional 1,186 shares during the last quarter. Bank of New York Mellon Corp increased its stake in CVRx by 4.5% in the fourth quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company's stock worth $385,000 after purchasing an additional 1,296 shares during the period. Rhumbline Advisers lifted its position in shares of CVRx by 13.0% during the first quarter. Rhumbline Advisers now owns 19,018 shares of the company's stock worth $233,000 after purchasing an additional 2,192 shares during the last quarter. Larson Financial Group LLC purchased a new stake in shares of CVRx during the first quarter valued at $28,000. Finally, Barclays PLC grew its holdings in shares of CVRx by 12.1% in the fourth quarter. Barclays PLC now owns 21,378 shares of the company's stock worth $270,000 after purchasing an additional 2,311 shares during the last quarter. Hedge funds and other institutional investors own 75.27% of the company's stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.